Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s DCGI Issues Warning Letter To Wyeth, GVK Over Trial

This article was originally published in PharmAsia News

Executive Summary

The Drug Controller General of India issued warning letters to U.S.-based Wyeth Pharmaceutical and a clinical trial monitor for violating Indian trial rules. The CDGI said an audit of a suspended trial of a pneumococcal vaccine in India disclosed violations of protocol, standard operating procedure and good clinical practices. The monitor was GVK Biosciences. DCGI ordered the trial suspended last November after the death of an infant, which the agency said protocol dictated should not have been included in the trial. The incident, involving a trial that began in 2007 with 350 children, is the first recorded in India. (Click here for more

Related Content

Citing Lack Of Infrastructure, Brakes Are Put On Allowing Phase I Trials In India
GVK Bio Says It Found No Link Between Wyeth Prevnar Vaccine And Child Death; Inspectors Did Not Check Documentation
With Wyeth, Pfizer To Become Second-largest Multinational Pharma In India



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts